Time to adjuvant chemotherapy for breast cancer in national comprehensive cancer network institutions

96Citations
Citations of this article
95Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background High-quality care must be not only appropriate but also timely. We assessed time to initiation of adjuvant chemotherapy for breast cancer as well as factors associated with delay to help identify targets for future efforts to reduce unnecessary delays. Methods Using data from the National Comprehensive Cancer Network (NCCN) Outcomes Database, we assessed the time from pathological diagnosis to initiation of chemotherapy (TTC) among 6622 women with stage I to stage III breast cancer diagnosed from 2003 through 2009 and treated with adjuvant chemotherapy in nine NCCN centers. Multivariable models were constructed to examine factors associated with TTC. All statistical tests were two-sided. Results Mean TTC was 12.0 weeks overall and increased over the study period. A number of factors were associated with a longer TTC. The largest effects were associated with therapeutic factors, including immediate postmastectomy reconstruction (2.7 weeks; P

Cite

CITATION STYLE

APA

Vandergrift, J. L., Niland, J. C., Theriault, R. L., Edge, S. B., Wong, Y. N., Loftus, L. S., … Weeks, J. C. (2013). Time to adjuvant chemotherapy for breast cancer in national comprehensive cancer network institutions. Journal of the National Cancer Institute, 105(2), 104–112. https://doi.org/10.1093/jnci/djs506

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free